Restricted content (Login to show the content)
Michael X. Repka, MD, MBA1; Katherine K. Weise, OD, MBA2; Danielle L. Chandler, MSPH3; et alRui Wu, MS3; B. Michele Melia, ScM3; Ruth E. Manny, OD, PhD4; Lori Ann F. Kehler, OD5; Catherine O. Jordan, MD6; Aparna Raghuram, OD, PhD7; Allison I. Summers, OD, MCR8; Katherine A. Lee, MD9; David B. Petersen, MD10; S. A. Erzurum, MD11; Yi Pang, OD, PhD12; Phoebe D. Lenhart, MD13; Benjamin H. Ticho, MD14; Roy W. Beck, MD, PhD3,15; Raymond T. Kraker, MSPH3; Jonathan M. Holmes, BM, BCh16; Susan A. Cotter, OD, MS17; for the Pediatric Eye Disease Investigator Group Author Affiliations Article Information JAMA Ophthalmol. 2023;141(8):756-765. doi:10.1001/jamaophthalmol.2023.2855 Key PointsQuestion Do low-dose atropine, 0.01%, eye drops delivered nightly over 2 years slow the…